N C Olson1, S Butenas2, L A Lange3, E M Lange3,4, M Cushman1,5, N S Jenny1, J Walston6, J C Souto7, J M Soria8, G Chauhan9,10, S Debette9,10,11,12, W T Longstreth13,14, S Seshadri12, A P Reiner14, R P Tracy1,2. 1. Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT, USA. 2. Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT, USA. 3. Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 4. Department of Biostatistics, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 5. Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA. 6. Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Department of Hematology, Institute of Biomedical Research (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 8. Unit of Genomics of Complex Diseases, Institute of Biomedical Research (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 9. INSERM U897, University of Bordeaux, Bordeaux, France. 10. University of Bordeaux, Bordeaux, France. 11. Bordeaux University Hospital, Bordeaux, France. 12. Department of Neurology, Boston University School of Medicine, Boston, MA, USA. 13. Department of Neurology, University of Washington, Seattle, WA, USA. 14. Department of Epidemiology, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: The relationships of thrombin generation (TG) with cardiovascular disease risk are underevaluated in population-based cohorts. OBJECTIVES: To evaluate the relationships of TG influenced by the contact and tissue factor coagulation pathways ex vivo with common single-nucleotide polymorphisms (SNPs) and incident cardiovascular disease and stroke. PATIENTS/ METHODS: We measured peak TG (pTG) in baseline plasma samples of Cardiovascular Health Study participants (n = 5411), both with and without inhibitory anti-factor XIa antibody (pTG/FXIa(-) ). We evaluated their associations with ~ 50 000 SNPs by using the IBCv2 genotyping array, and with incident cardiovascular disease and stroke events over a median follow-up of 13.2 years. RESULTS: The minor allele for an SNP in the FXII gene (F12), rs1801020, was associated with lower pTG in European-Americans (β = - 34.2 ± 3.5 nm; P = 3.3 × 10(-22) ; minor allele frequency [MAF] = 0.23) and African-Americans (β = - 31.1 ± 7.9 nm; P = 9.0 × 10(-5) ; MAF = 0.42). Lower FXIa-independent pTG (pTG/FXIa(-) ) was associated with the F12 rs1801020 minor allele, and higher pTG/FXIa(-) was associated with the ABO SNP rs657152 minor allele (β = 16.3 nm; P = 4.3 × 10(-9) ; MAF = 0.37). The risk factor-adjusted ischemic stroke hazard ratios were 1.09 (95% confidence interval CI 1.01-1.17; P = 0.03) for pTG, 1.06 (95% CI 0.98-1.15; P = 0.17) for pTG/FXIa(-) , and 1.11 (95% CI 1.02-1.21; P = 0.02) for FXIa-dependent pTG (pTG/FXIa(+) ), per one standard deviation increment (n = 834 ischemic strokes). In a multicohort candidate gene analysis, rs1801020 was not associated with incident ischemic stroke (β = - 0.02; standard error = 0.08; P = 0.81). CONCLUSIONS: These results support the importance of contact activation pathway-dependent TG as a risk factor for ischemic stroke, and indicate the importance of F12 SNPs for TG ex vivo and in vivo.
BACKGROUND: The relationships of thrombin generation (TG) with cardiovascular disease risk are underevaluated in population-based cohorts. OBJECTIVES: To evaluate the relationships of TG influenced by the contact and tissue factor coagulation pathways ex vivo with common single-nucleotide polymorphisms (SNPs) and incident cardiovascular disease and stroke. PATIENTS/ METHODS: We measured peak TG (pTG) in baseline plasma samples of Cardiovascular Health Study participants (n = 5411), both with and without inhibitory anti-factor XIa antibody (pTG/FXIa(-) ). We evaluated their associations with ~ 50 000 SNPs by using the IBCv2 genotyping array, and with incident cardiovascular disease and stroke events over a median follow-up of 13.2 years. RESULTS: The minor allele for an SNP in the FXII gene (F12), rs1801020, was associated with lower pTG in European-Americans (β = - 34.2 ± 3.5 nm; P = 3.3 × 10(-22) ; minor allele frequency [MAF] = 0.23) and African-Americans (β = - 31.1 ± 7.9 nm; P = 9.0 × 10(-5) ; MAF = 0.42). Lower FXIa-independent pTG (pTG/FXIa(-) ) was associated with the F12rs1801020 minor allele, and higher pTG/FXIa(-) was associated with the ABO SNP rs657152 minor allele (β = 16.3 nm; P = 4.3 × 10(-9) ; MAF = 0.37). The risk factor-adjusted ischemic stroke hazard ratios were 1.09 (95% confidence interval CI 1.01-1.17; P = 0.03) for pTG, 1.06 (95% CI 0.98-1.15; P = 0.17) for pTG/FXIa(-) , and 1.11 (95% CI 1.02-1.21; P = 0.02) for FXIa-dependent pTG (pTG/FXIa(+) ), per one standard deviation increment (n = 834 ischemic strokes). In a multicohort candidate gene analysis, rs1801020 was not associated with incident ischemic stroke (β = - 0.02; standard error = 0.08; P = 0.81). CONCLUSIONS: These results support the importance of contact activation pathway-dependent TG as a risk factor for ischemic stroke, and indicate the importance of F12 SNPs for TG ex vivo and in vivo.
Authors: Marijke J E Kuijpers; Paola E J van der Meijden; Marion A H Feijge; Nadine J A Mattheij; Frauke May; José Govers-Riemslag; Joost C M Meijers; Johan W M Heemskerk; Thomas Renné; Judith M E M Cosemans Journal: Arterioscler Thromb Vasc Biol Date: 2014-05-22 Impact factor: 8.311
Authors: Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani Journal: Blood Date: 2014-01-09 Impact factor: 22.113
Authors: M Cushman; R N Lemaitre; L H Kuller; B M Psaty; E M Macy; A R Sharrett; R P Tracy Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: Olivier Segers; René van van Oerle; Hugo ten ten Cate; Jan Rosing; Elisabetta Castoldi Journal: Thromb Haemost Date: 2009-11-13 Impact factor: 5.249
Authors: Bruce M Psaty; Christopher J O'Donnell; Vilmundur Gudnason; Kathryn L Lunetta; Aaron R Folsom; Jerome I Rotter; André G Uitterlinden; Tamara B Harris; Jacqueline C M Witteman; Eric Boerwinkle Journal: Circ Cardiovasc Genet Date: 2009-02
Authors: Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt Journal: J Exp Med Date: 2005-07-11 Impact factor: 14.307
Authors: Daniel H Katz; Usman A Tahir; Alexander G Bick; Akhil Pampana; Debby Ngo; Mark D Benson; Zhi Yu; Jeremy M Robbins; Zsu-Zsu Chen; Daniel E Cruz; Shuliang Deng; Laurie Farrell; Sumita Sinha; Alec A Schmaier; Dongxiao Shen; Yan Gao; Michael E Hall; Adolfo Correa; Russell P Tracy; Peter Durda; Kent D Taylor; Yongmei Liu; W Craig Johnson; Xiuqing Guo; Jie Yao; Yii-Der Ida Chen; Ani W Manichaikul; Deepti Jain; Claude Bouchard; Mark A Sarzynski; Stephen S Rich; Jerome I Rotter; Thomas J Wang; James G Wilson; Pradeep Natarajan; Robert E Gerszten Journal: Circulation Date: 2021-11-24 Impact factor: 39.918
Authors: Weihua Zhang; Fredrik Jernerén; Benjamin C Lehne; Ming-Huei Chen; Robert N Luben; Carole Johnston; Amany Elshorbagy; Ruben N Eppinga; William R Scott; Elizabeth Adeyeye; James Scott; Rainer H Böger; Kay-Tee Khaw; Pim van der Harst; Nicholas J Wareham; Ramachandran S Vasan; John C Chambers; Helga Refsum; Jaspal S Kooner Journal: Thromb Haemost Date: 2016-09-22 Impact factor: 5.249